Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00293150
Other study ID # 6242
Secondary ID
Status Terminated
Phase Phase 4
First received February 16, 2006
Last updated January 26, 2017
Start date September 2003
Est. completion date September 2007

Study information

Verified date January 2017
Source The Cleveland Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The principle aim is to determine the efficacy of eplerenone in patients with diastolic heart failure to reverse cardiac remodeling and to improve diastolic function.


Description:

The study will be a single center, double-blind, randomized, parallel group trial enrolling a minimum of 80 patients designed to determine the efficacy of eplerenone in subjects with diastolic heart failure. Prior to administration of study medication, a medical history, physical exam, blood draw, electrocardiogram, 2D echocardiogram, and cardiomyopathy questionnaire will be performed. Subjects will then be randomized to receive either eplerenone 25 mg once daily or placebo for 2 weeks. At the Week 2 visit all patients will be titrated up to the next dose (50 mg eplerenone once daily or placebo). Each study arm will have 40 subjects who will participate for 9 months. Follow-up assessments will be completed at 1 week, 2 weeks, 1 month, 3 months, 6 months, and 9 months.

Starting at the Month 1 visit, any subjects with uncontrolled blood pressure will be administered add-on therapy of HCTZ (starting dose of 12.5 mg daily, that may titrate up to 25 mg daily) and/or amlodipine (starting dose at 5 mg daily, that may titrate up to 10 mg daily). Any subject who receives add-on therapy must have their blood pressure checked within 2 weeks. Uncontrolled blood pressure may be treated by either increasing the add-on therapy dose or increasing the add-on therapy regimen to include both add-on drugs. Changes in add-on therapy require blood pressure checks within 2 weeks.


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date September 2007
Est. primary completion date September 2007
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study:

1. Male or non-pregnant female (if female, either post-menopausal, or if of child-bearing potential, using adequate contraception e.g. hormonal or barrier methods, or surgically sterile, and not lactating)

2. Age >/= 18 years of age

3. Present or prior history of symptoms of heart failure (dyspnea, fatigue) consistent with diagnosis of diastolic heart failure, following optimized medical therapy including blood pressure control with ACE inhibitors and/or beta-blockers for 2 weeks or over.

4. Echocardiographic evidence of preserved left ventricular systolic function (LVEF >/= 45%) and evidence of diastolic dysfunction (by transmitral inflow, pulmonary venous flow, color M-mode and/or tissue Doppler).

5. Signed informed consent

Exclusion Criteria:

The presence of any of the following will exclude a patient from study enrollment:

1. Unwilling to participate for the 9-month duration of the study

2. Significant primary valvular, pulmonary or congenital cardiac disease believed to be the cause of dyspnea

3. Life expectancy or planned cardiac transplantation <9 months

4. History of hypertrophic obstructive cardiomyopathy

5. Unstable angina or ischemia requiring revascularization

6. Renal insufficiency (Cr >2.0 mg/dL in males and >1.8 mg/dl in females, or modified Cockcroft-Gault estimate of creatinine clearance <30 mL/min) at enrollment

7. Known hypersensitivity to spironolactone or eplerenone

8. Decompensated heart failure or clinical evidence of instability at the time of enrollment 9 History of hyperkalemia (>6.0 mg/dL) with spironolactone

10. Use of spironolactone or amiloride within 30 days 11. Poorly controlled seating blood pressure at the time of drug initiation:

- Systolic blood pressure >160 mmHg; and/or

- Diastolic blood pressure >100 mmHg

Study Design


Intervention

Drug:
Eplerenone


Locations

Country Name City State
United States The Cleveland Clinic Cleveland Ohio

Sponsors (1)

Lead Sponsor Collaborator
The Cleveland Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of eplerenone Improved diastolic function 9 months
Secondary Degree of change degree of changes in natriuretic peptide production, endothelial function and collagen turnover 9 months
See also
  Status Clinical Trial Phase
Recruiting NCT02499601 - CORolla® TAA for Heart Failure With Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction (DD) N/A
Completed NCT02537041 - Non-invasive Evaluation of Myocardial Stiffness by Elastography N/A
Completed NCT02275793 - The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
Withdrawn NCT00773084 - Aliskiren and Renin Inhibition in Diastolic Heart Failure N/A
Terminated NCT01942395 - Dietary Approaches to Stop Hypertension in 'Diastolic' Heart Failure 2 (DASH-DHF 2) N/A
Recruiting NCT03157219 - Manipal Heart Failure Registry (MHFR) N/A
Terminated NCT01778894 - Mathematical Modeling to Determine Basic Muscle Properties in the Failing Heart
Completed NCT04154878 - 2 New Measurements Used to Describe the Filling Phase of the Left Ventricle (LV).
Recruiting NCT01599117 - A Randomized Trial of Udenafil Therapy in Patients With Heart Failure With Preserved Ejection Fraction [ULTIMATE-HFpEF] Phase 3
Completed NCT01185067 - Physiological Effects of Grape Seed Extract in Diastolic Heart Failure Phase 1
Completed NCT03338374 - Cardiac Resynchronisation Therapy Versus Rate-responsive Pacing in Heart Failure With Preserved Ejection Fraction N/A
Completed NCT02589977 - Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF Phase 4
Completed NCT02147613 - High Intensity Interval Exercise in Diastolic Heart Failure N/A
Terminated NCT00083772 - Use of Nesiritide in the Management of Acute Diastolic Heart Failure Phase 4
Completed NCT00303498 - A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure Phase 2
Terminated NCT02254382 - Positive Airway Pressure Therapy Study in Sleep Apnea and Diastolic Heart Failure N/A
Completed NCT00839228 - Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome Phase 2
Terminated NCT00662116 - Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I) Phase 2
Completed NCT02916225 - High Intensity Interval Training Versus Moderate Continuous Training in Heart Failure With Preserved Ejection Fraction N/A
Completed NCT02084992 - A Study of a Technology-enabled Disease Management Program to Reduce Hospitalizations for Heart Failure N/A